Nirsum Labs was founded in response to the US epidemic of opioid use disorder (OUD).
OUD is a chronic and typically relapsing condition. FDA-approved medication-assisted treatment (MAT) is the gold-standard therapy for OUD, alongside psychosocial support. While patient access to MAT is increasing, adherence and retention rates are poor, like with early HIV therapies. Nirsum is developing novel drugs to combat the OUD crisis, with potentially superior adherence, retention, and efficacy versus currently available MAT options, bringing urgently needed help to those in need.
Nikej Shah, MD
Chief Executive Officer
Michael Tusche, Ph.D.
Vice President of R&D
Dr. Michael Tusche is Co-Founder, Vice President of R&D, and Co-Inventor of Nirsum’s foundational intellectual property.
“[The opioid crisis] is the most profound public health crisis facing the U.S. Food and Drug Administration and Americans… One of the critical ways the FDA can play a role is by encouraging more widespread innovation and development of medication for use in medication-assisted treatments (MAT)” – US FDA Commissioner Dr. Scott Gottlieb
New York200 Vesey Street, 24th Floor
New York, NY 10281